pharmaceutical company funds protandim study

---

BIOGEN, maker of Tecfidera funded an independent study to see which product is a better NRF2 activator:

Tecfidera ($10,000/month drug) or Protandim NRF2 ($60/month plant-based NRF2 Activator)

*We do not claim to diagnose, treat, cure,  mitigate or prevent disease. 

**These statements have not been evaluated by the FDA.